Elsevier

Clinical Therapeutics

Volume 27, Issue 8, August 2005, Pages 1278-1294
Clinical Therapeutics

Development and validity testing of the neuropathy total symptom score-6: Questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy*

https://doi.org/10.1016/j.clinthera.2005.08.002Get rights and content

Abstract

Objective:

The aim of this study was to develop and validate a neuropathy sensory symptom scale, the Neuropathy Total Symptom Score-6 (NTSS-6), which evaluates individual neuropathy sensory symptoms in patients with diabetes mellitus (DM) and diabetic peripheral neuropathy (DPN) in clinical trials, with the intent of distinguishing a response to therapy.

Methods:

The NTSS-6 questionnaire was developed to evaluate the frequency and intensity of individual neuropathy sensory symptoms identified frequently by patients with DPN (ie, numbness and/or insensitivity; prickling and/or tingling sensation; burning sensation; aching pain and/or tightness; sharp, shooting, lancinating pain; and allodynia and/or hyperalgesia). The NTSS-6 was administered 8 times over a 1-year period to DPN patients. The NTSS-6's reliability (determined by internal consistency and test-retest reproducibility), construct validity, convergent validity, and minimally clinically important differences (MCIDs) were determined.

Results:

The NTSS-6 was administered to a total of 205 patients at 10 centers in the United States, Canada, Belgium, Germany, Hungary, Croatia, Slovenia, and the United Kingdom. Internal consistency was demonstrated at all 8 visits (Cronbach's α > 0.7). Test-retest reproducibility (intraclass correlation coefficient >0.9) was observed during the baseline period and at end point. Construct validity was demonstrated by statistically significant correlations between the NTSS-6 total score and the Neuropathy Symptoms and Change (NSC) score (r = 0.773−0.885, P < 0.001). Convergent validity was demonstrated by statistically significant correlations between the change in NTSS-6 total scores and the following: change in NSC scores (r = 0.519−0.708, P < 0.001); change in Neuropathy Impairment Score of the Lower Limbs and composite nerve function scores (r = 0.188−0.202, P < 0.007), and categories of the Clinical Global Impressions (r = 0.402, P < 0.001). The within- and between-groups MCIDs for the total NTSS-6 total scores were −1.26 and 0.97 points, respectively. The mean (SD) within-group MCID for all patients who improved on the Clinical Global Impression was −2.29 (3.4) points.

Conclusions:

The NTSS-6 provided a valid assessment of neuropathy sensory symptoms in this sample of patients with DM and DPN, which suggests that it may be useful for symptom evaluation in clinical trials and practice. The NTSS-6 showed internal consistency, test-retest reliability, and construct validity. There was also convergent validity of the scores, indicating that the NTSS-6 may be a suitable questionnaire for clinical trials that evaluate symptoms of DPN in this well-defined patient population.

References (60)

  • NelsenLM et al.

    Quality-of-life questionnaire for patients taking antihypertensive medication

    Clin Ther

    (1999)
  • GuyattGH et al.

    Methods to explain the clinical significance of health status measures

  • VinikAI et al.

    Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial

    Clin Ther

    (2005)
  • DyckPJ et al.

    The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study

    Neurology

    (1993)
  • TesfayeS et al.

    Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM Complications Study

    Diabetologia

    (1996)
  • MaserRE et al.

    Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study

    Diabetes

    (1989)
  • FedeleD et al.

    A multicenter study on the prevalence of diabetic neuropathy in Italy

    Diabetes Care

    (1997)
  • YoungMJ et al.

    A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population

    Diabetologia

    (1993)
  • ApfelSC et al.

    Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials

    J Neurol Sci

    (2001)
  • BoultonAJ et al.

    Diabetic somatic neuropathies

    Diabetes Care

    (2004)
  • HarrisM et al.

    Symptoms of sensory neuropathy in adults with NIDDM in the US population

    Diabetes Care

    (1993)
  • BoultonAJ et al.

    The prevalence of symptomatic, diabetic neuropathy in an insulin-treated population

    Diabetes Care

    (1985)
  • MarchettiniP et al.

    Pain in diabetic neuropathy case study: Whole patient management

    Eur J Neurol

    (2004)
  • O'HareJA et al.

    Prevalence and forms of neuropathic morbidity in 800 diabetics

    Jr J Med Sci

    (1994)
  • HongCY et al.

    Neuropathy in non-insulin-dependent diabetes mellitus. The significance of symptoms

    Scand J Prim Health Care

    (1998)
  • Standards of medical care in diabetes (Position Statement)

    Diabetes Care

    (2005)
  • BastyrEJ et al.

    Neuropathy Total Symptom Score-6 Questionnaire (NTSS-6) is a valid instrument for assessing the positive symptoms of diabetic peripheral neuropathy (DPN)

    Diabetes

    (2002)
  • DyckPJ et al.

    Electronic case-report forms of symptoms and impairments of peripheral neuropathy

    Can J Neurol Sci

    (2002)
  • BackonjaM et al.

    Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial

    JAMA

    (1998)
  • Cited by (158)

    • Mast cell disorders are associated with decreased cerebral blood flow and small fiber neuropathy

      2022, Annals of Allergy, Asthma and Immunology
      Citation Excerpt :

      For all patients in the HαT and MCAS groups, validated neurologic symptom surveys were completed at the time of autonomic testing. Sensory complaints were surveyed by the Neuropathy Total Symptom Score—6 (NTSS) which is a validated instrument for evaluation of pain features.13 NTSS quantifies sensory symptoms (aching pain, allodynia, burning pain, lancinating pain, numbness, and prickling sensation).

    View all citing articles on Scopus
    *

    Express Track online publication August 16, 2005.

    *

    All MBBQ Study Group principal investigators and sites are listed in the Acknowledgments.

    View full text